SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending as a new U.S. manufacturing partnership with Nanotech Energy establishes a crucial domestic production pathway for its high-performance silicon anode batteries, particularly vital for defense and drone applications. The community is actively discussing the company's capital-light growth strategy and its potential for significant revenue expansion and profitability this year, further fueled by recent analyst upgrades.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is a major talking point as its community actively discusses a significant tokenomics redesign, aiming to transition from inflationary rewards to a revenue-based model for enhanced value. This initiative, alongside its "Internet of Blockchains" vision and high staking yields, is being closely watched amidst evolving crypto market sentiment and anticipation of regulatory clarity.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending following its decision to pause the SER-155 Phase 2 study and implement a significant workforce reduction, signaling a strategic shift towards earlier-stage programs and extending its cash runway. The market is reacting to this pivot, while the community actively discusses the implications for the company's future, with many debating if these moves position the company for an eventual buyout or if upcoming SER-155 irEC data will be the crucial catalyst for partnership.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending due to its imminent token halving and recent Binance Japan listing, amplified by Grayscale's ETF filing, fueling community discussion around its scarce tokenomics and potential as the "Bitcoin of AI" for decentralized intelligence. Investors are actively exploring staking opportunities within its innovative subnet ecosystem as a key talking point.

Polygon

Polygon (POL) is trending as it cements its position as a foundational layer for regulated payments and Real-World Assets (RWAs) through significant acquisitions and surging stablecoin transaction volumes. The community remains actively engaged with its ongoing network upgrades, like the AggLayer, and proposed token burns, weighing these strong fundamentals against current market price action.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending as its Vevye product experiences surging prescription growth driven by major PBM formulary wins and an expanded sales force, with positive news around pipeline developments and regulatory resolutions fueling community discussions about significant revenue acceleration and potential short-covering.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending higher amid escalating global geopolitical tensions, particularly regarding potential US military action, which is driving investor expectations for increased defense spending and a strong rally in the defense sector. The company's recent positive earnings, optimistic guidance, and plans to significantly boost missile production are fueling community discussion and bullish sentiment despite its sharp price appreciation.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending following its selection as the first qualified vendor for the U.S. Army's Ground Vehicle Systems Center and renewed institutional interest. The community is actively discussing the company's critical role in defense and aerospace manufacturing, expecting significant growth and a potential short squeeze fueled by partnerships with entities like SpaceX and Anduril.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending due to escalating speculation about a potential buyout by major tech players like SpaceX or Amazon, leveraging its uniquely valuable n53 spectrum and deepening Apple partnership for direct-to-device connectivity. The community eagerly anticipates key FCC decisions regarding spectrum use and the C-3 constellation, which are seen as critical catalysts to unlock the company's significant undervalued assets and emerging IoT solutions.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is trending due to a significant sell-off following strong earnings, sparking an intense community debate on whether the broader software sector faces an existential AI threat or if the stock represents a deeply undervalued buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bio-Rad Laboratories (NYSE:BIO) Lowered to "Hold" Rating by Wall Street Zen

Wall Street Zen cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday...

Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Here's What Happened

Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Should You Sell...

Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss

Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss...

Bio-Rad Laboratories Q4 Earnings Call Highlights

Bio-Rad Laboratories (NYSE:BIO) executives said the company finished 2025 within revised guidance for revenue and operating margin, but acknowledged that gross margin performance fell short of...

Bio-Rad Laboratories (NYSE:BIO.B) Posts Quarterly Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) announced its quarterly earnings data on Thursday. The company reported $2.51 earnings per share for the quarter. Bio-Rad Laboratories had a...

Bio-Rad Laboratories (BIO) Q4 Earnings Miss Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of -2.34% and +0.01%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (NYSE:BIO) Announces Quarterly Earnings Results

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) posted its earnings results on Thursday. The medical research company reported $2.51 earnings per share for the quarter, missing analysts' consensus...

Earnings Summary: Bio-Rad Laboratories Q4

Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year...

Allianz Asset Management GmbH Boosts Position in Bio-Rad Laboratories, Inc. $BIO

Allianz Asset Management GmbH raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 22.7% during the 3rd quarter, according to its most recent disclosure with the Securities...

$BIO Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $26.69 up 204.38% YoY
• Reported revenue of $693.2M up 3.85% YoY
• Bio-Rad expects non-GAAP currency neutral revenue growth of approximately 0.5% to 1.5% and an estimated non-GAAP operating margin of 12.0% to 12.5% for the full-year 2026.

Stocktwits

Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $26.69 up 204.38% YoY
• Reported revenue of $693.2M up 3.85% YoY
• Bio-Rad expects non-GAAP currency neutral revenue growth of approximately 0.5% to 1.5% and an estimated non-GAAP operating margin of 12.0% to 12.5% for the full-year 2026.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

BIO
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BIO News

BIOBio-Rad Laboratories Inc. - Ordinary Shares - Class A